0001209191-18-033230.txt : 20180524
0001209191-18-033230.hdr.sgml : 20180524
20180524200220
ACCESSION NUMBER: 0001209191-18-033230
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180522
FILED AS OF DATE: 20180524
DATE AS OF CHANGE: 20180524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Curnutte John T
CENTRAL INDEX KEY: 0001574589
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 18859408
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-22
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001574589
Curnutte John T
C/O PORTOLA PHARMACEUTICALS, INC.
270 EAST GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive Vice President
Common Stock
2018-05-22
4
A
0
4687
0.00
A
119902
D
Common Stock
2018-05-22
4
F
0
1647
40.82
D
118255
D
Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 4,687 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 4,688 PSUs will vest on the first anniversary of the Certification Date.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
/s/ Mike Ouimette, as attorney-in-fact
2018-05-24